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In 1994, when we introduced the ultra-
fine particle hypothesis stating that
ambient ultrafine particles (UFP; < 0.1
µm in aerodynamic diameter) may cause
adverse health effects at the first
Colloquium for Particulate Air Pollution
and Human Mortality and Morbidity in Irvine, California, it was
met with friendly skepticism as well as out-right dismissal. Arguments
were that UFP are very short-lived and disappear through heteroge-
neous and homogeneous aggregation within seconds or minutes and
therefore are toxicologically irrelevant. These arguments did not rec-
ognize that UFP are continuously generated or that ambient UFP
contribute very little, if any, mass to ambient PM10 (particles < 10
µm in aerodynamic diameter) or PM2.5 (particles < 2.5 µm in aerody-
namic diameter). Indeed, the mass distribution of a typical urban
aerosol among the different particle sizes may support this point
(Figure 1). This attitude of skepticism has changed considerably.
Research teams across the world are working now on UFP, forming
multidisciplinary alliances between atmospheric scientists, engineers,
epidemiologists, clinicians, and toxicologists. They investigate UFP
sources, generation, physicochemical characteristics, behavior in
ambient air, and potential effects and underlying mechanisms follow-
ing their inhalation. Still, sound skepticism lingers, as demonstrated
by the title of a presentation at the 2002 meeting of the Health
Effects Institute: “Nanoparticles: Are They Real?”
Obviously, there is no question that UFP are real, but it is also clear
that we still do not know enough about them, despite significant
progress in our understanding since 1994. Atmospheric UFP derived
from gas-to-particle conversions have many sources, natural and anthro-
pogenic, the latter being mostly derived from internal combustion
processes. Diesel fuel, gasoline, and even
compressed natural gas—considered to
be “clean”—powered engines all emit
high numbers of UFP. If these anthro-
pogenic UFP cause significant health
effects, is the conversion of diesel-
powered buses to compressed natural gas—as practiced now in several
cities—really a good idea? We should be more cautious about intro-
ducing technologies based on the assumption that they result in clean-
er air with fewer and less toxic contaminants. The experience with
methyl tert-butyl ether as a fuel additive should serve as a reminder of
the potential unintended health and environmental consequences of
altering fuels and resulting emissions on a large scale without an ade-
quate understanding of toxicity.
Since vehicular emissions are regulated by mass output, modern
technologies for internal combustion engines favor the generation and
formation of UFP because they contribute minimally to the mass out-
put of fine particles (Figure 1). It should come as no surprise that
“clean” engines are built to conform to present standards of mass out-
put, despite emitting high numbers of UFP. A standard based on par-
ticle number would be more appropriate to reduce UFP emissions. A
standard based on particle surface area—as is also proposed—may not
be helpful to control UFP because fine particles comprise most of the
total particle surface area (Figure 1). In recent measurements made
during road-chase studies in Minnesota, UFP concentrations were as
high as 1 × 107 particles/cm3 (Kittelson et al. 2001). A short distance
from the highways, these high UFP concentrations are lower, but
individuals in automobiles on the highways are directly exposed to the
high concentrations. Moreover, these UFP are freshly generated, and
if results of earlier toxicologic studies with UFP generated from
thermodegradation products of polymers are an indication of a general
principle of UFP toxicity, freshness and proximity to the source are
key requirements for inducing acute adverse effects of UFP.
Do UFP emitted from internal combustion engines cause adverse
health effects? We still need to know more, but results from our con-
trolled clinical and animal studies using ultrafine elemental carbon par-
ticles permit some preliminary conclusions: The high deposition of
inhaled UFP (0.007–0.1 µm) in the human respiratory tract as predict-
ed by ICRP (1994) could be confirmed; moreover, deposition was even
higher during exercise and in asthmatics. Unlike larger fine particles,
UFP seem to escape phagocytosis by alveolar macrophages and are
translocated to extrapulmonary organs, as was determined in rodents
using ultrafine 13C particles, although such translocation was only min-
imal with ultrafine iridium particles. Cardiovascular effects in humans
and animals and mild pulmonary inflammation in animals were also
found following ultrafine carbon particle exposures.
Although health effects data and understanding of mechanisms are
still limited, there are intriguing data from other disciplines, in particular
the field of drug delivery: Intravenously administered UFP were found
to cross the blood–brain barrier (Kreuter, 2001), and a transport func-
tion of caveolae for macromolecules with molecular radii of several
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Figure 1. Typical urban particle size distribution based on the work of Finlayson-
Pitts and Pitts (2000). In this editorial, ultrafine particles are considered to be
those < 0.1 µm, but there is no general consensus about this definition; the term
“nanoparticles” has also been used for particles < 0.01 µm, as shown.
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nanometers across the alveolar–capillary barrier as a pathway for protein
delivery from lung to blood seems to exist (Gumbleton, 2001); could
this be a mechanism for solid UFP transport as well, given that the
openings of the caveolae range between 0.04 and 0.1 µm? Intriguing as
well is the apparent existence of still another, more direct, pathway of
UFP deposited in the respiratory tract to extrapulmonary organs via
neurons, including transsynaptic transport. This was first reported by
Howe and Bodian (1940) for 0.03-µm polio virus in monkeys and was
later described for nasally deposited colloidal 0.05-µm gold particles
moving into the olfactory bulb of squirrel monkeys (de Lorenzo 1970).
Ultrafine carbon particles may translocate along the same pathway to
the central nervous system (CNS), based on our recent finding of these
particles in the olfactory bulb of rats after their inhalation. 
A fascinating question is whether the CNS is another target organ
for inhaled UFP. If so, could this mean that some effects of UFP on
cardiovascular function are mediated via the autonomic nervous sys-
tem? In this context, Calderon-Garciduenas et al. (2002) reported sig-
nificant histologic lesions in olfactory bulb and other brain regions
and olfactory mucosa of dogs in Mexico City—with high air pollu-
tion—compared to dogs from a clean rural area. Their study did not
establish a causal association between PM, or specifically UFP, and
CNS effects, but it appears that the evidence is accumulating and
becoming stronger that urban UFP are more than a nuisance.
The advances in our understanding of UFP kinetics and effects
open many more questions, including evaluation of the importance of
organic versus elemental ultrafine carbon particles; metal constituents
of these particles with respect to their existence on the same or on dif-
ferent UFP; biologic/toxicologic activity of freshly generated versus
aged ambient UFP; mechanisms of extrapulmonary transport; and
direct versus indirect effects of UFP on extrapulmonary organs, includ-
ing the CNS. With the emergence of so many unanswered questions,
the health consequences of inhalation of UFP remain an important
area of investigation. 
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